| 11.98 0.06 (0.5%) | 08-28 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term | |
|||
| Targets | 6-month : | 1-year : | ||
| Resists | First : | Second : | ||
| Pivot price | ||||
| Supports | First : | Second : | ||
| MAs | MA(5) : | MA(20) : | ||
| MA(100) : | MA(250) : | |||
| MACD | MACD : | Signal : | ||
| %K %D | K(14,3) : | D(3) : | ||
| RSI | RSI(14): | |||
| 52-week | High : | Low : | ||
| If tomorrow: | Open lower | Open higher |
| High: | - | - |
| Low: | - | - |
| Close: | - | - |
Walgreens Boots Alliance, Inc., established in 1901 and based in Deerfield, Illinois, operates as a leading global retailer focused on pharmacy, health, and beauty products. Its business activities are organized into two primary divisions: the United States and International. In the United States, the company dispenses prescription drugs and offers a diverse selection of retail goods. This includes items for health, wellness, beauty, and personal care, alongside general merchandise and consumable products, all available through its extensive network of retail drugstores. The U.S. segment also provides specialized central pharmacy services and mail delivery options for prescriptions. As of August 31, 2021, this division managed 8,965 retail outlets under the Walgreens and Duane Reade banners, complemented by five specialty pharmacies. The International segment focuses on the sale of prescription medications, health and wellness items, beauty products, personal care essentials, and other consumer goods. These are sold through its pharmacy-centric health and beauty retail locations, optical practices, its online platform boots.com, and an integrated mobile application. Additionally, this segment engages in pharmaceutical wholesale and distribution operations within Germany. By August 31, 2021, the international portfolio included 4,031 retail stores operating under brands such as Boots, Benavides, and Ahumada, located across countries including the United Kingdom, Thailand, Norway, the Republic of Ireland, the Netherlands, Mexico, and Chile. It also oversaw 548 optical practices, with 160 of these operating as franchises.
Tue, 16 Jun 2026
Walgreens Boots Alliance Inc (WBA) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Mon, 08 Jun 2026
Walgreens Boots Alliance Shareholders Overwhelmingly Approve Transaction with Sycamore Partners - Walgreens
Tue, 23 Dec 2025
The Fall and Fragmentation of a Giant: A Post-Mortem and Future Outlook on Walgreens Boots Alliance (WBA) - FinancialContent
Sat, 06 Dec 2025
Walgreens Boots Alliance (WBA) Stock in December 2025: Buyout Price, Delisting, and What’s Left for Investors - TechStock²
Mon, 22 Sep 2025
Does Walgreens Boots Alliance's (WBA) SEC Deregistration Plan Signal a Shift in Investor Engagement? - simplywall.st
Mon, 01 Sep 2025
Boots and Walgreens become independent after Sycamore Partners’ buyout - Personal Care Insights
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Medical - Pharmaceuticals
|
|
| Shares Out | 0 (M) |
| Shares Float | 0 (M) |
| Held by Insiders | (%) |
| Held by Institutions | (%) |
| Shares Short | 0 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | |
| EPS Est Next Qtrly | |
| EPS Est This Year | |
| EPS Est Next Year | |
| Book Value (p.s.) | |
| Profit Margin | % |
| Operating Margin | % |
| Return on Assets (ttm) | % |
| Return on Equity (ttm) | % |
| Qtrly Rev. Growth | % |
| Gross Profit (p.s.) | |
| Sales Per Share | |
| EBITDA (p.s.) | |
| Qtrly Earnings Growth | % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | 0 (M) |
| PE Ratio | |
| PEG Ratio | |
| Price to Book value | |
| Price to Sales | |
| Price to Cash Flow |
| Dividend | |
| Forward Dividend | |
| Dividend Yield | 0% |
| Dividend Pay Date | |
| Ex-Dividend Date |
|
|
|
|
|
|
|
|
|